drugset / Trial / NCT01916850

Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects

NCT01916850

Phase 1 Completed 25 enrolled Lexicon Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the safety and tolerability of multiple oral doses of LX4211 400 mg and LX4211 800 mg (administered once daily for 10 consecutive days) in healthy subjects.

Timeline

Start
2013-08
Primary completion
2013-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Sotagliflozin Small molecule 400 mg Oral
Subject Sotagliflozin Small molecule 800 mg Oral

Indications

No indication recorded.